Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Visa Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.51 (market cap $8.04B), while Visa Inc trades at $356.85 (market cap $677.06B). The key difference: Visa Inc is far larger — about 84.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Visa Inc pays a 0.75% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | V | |
|---|---|---|
Market Cap | $8.04B | $677.06B |
Sector | Health | Financials |
52-Week High | $339.75 | $362.13 |
52-Week Low | $241.71 | $295.52 |
Enterprise Value | $7.85B | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Visa (V) trades at $355.01, down 0.77% on the day, but maintains strong technical momentum with bullish moving averages and key support at $354. The company demonstrates robust fundamentals with consistent earnings beats, 51.68% net income margins, and 16.28% ROE. Recent developments include the launch of Intelligent Commerce Connect for AI-driven commerce and stablecoin partnerships, positioning Visa at the forefront of payment innovation.
Visa presents a compelling long-term investment with 85% analyst buy ratings and a $394.50 consensus price target implying 11% upside. Risks include fintech disruption and regulatory pressures, but the company's dominant market position, expanding revenue base, and strong cash flow generation support continued shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
